Consistent with our analysis showing a correlation between high ADAMTS5 expression and poor patient prognosis in OC, ADAMTS5 was shown to be a tumour promoter in glioblastoma [49], non‐small cell lung cancer [50] and head and neck cancer [51], while in melanoma and gastric carcinoma, ADAMTS5 was found to suppress tumour progression by inhibiting angiogenesis in a catalytic activity‐independent manner [52, 53]. Here, ADAMTS5 is linked to melanoma.